{"entity":{"id":"nct02411448","kind":"trial","name":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE","aka":["RELAY"],"tldr":"A phase 3 trial of Ramucirumab, Erlotinib, Gefitinib in non-small-cell lung cancer and small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting.","summary":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) is a phase 3 interventional study registered as NCT02411448 by Eli Lilly and Company, with 545 participants enrolled, started 2015-05-06 and due to reach its primary completion in 2019-01-23. Interventions recorded: Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib. Conditions listed: Metastatic Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2020; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02411448","url":"https://clinicaltrials.gov/study/NCT02411448"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","egfr-mutant-nsclc"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors","monoclonal-antibody"],"targets":[],"drugs":["ramucirumab","erlotinib","gefitinib","osimertinib"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct02411448-lancet-oncol-2019","paper-nct02411448-j-thorac-oncol-2025-update"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02411448","phase":"3","setting":"A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer","sponsor":"Eli Lilly and Company","started":"2015-05-06","startedType":"actual","yearReported":2020,"enrolled":545,"enrolledBasis":"registry","outcomes":[{"endpoint":"Part B: Progression Free Survival (PFS)","primary":true,"unit":"months","arms":[{"name":"Part B: Ramucirumab+ Erlotinib","n":224,"value":19.4,"note":"95% CI 15.4 to 21.6; Figures from the ClinicalTrials.gov results section (first posted 2020-03-04), not from a publication"},{"name":"Part B: Placebo+ Erlotinib","n":225,"value":12.4,"note":"95% CI 11.0 to 13.5"}],"hr":0.591,"ci":[0.461,0.76],"p":"<0.0001","source":"https://clinicaltrials.gov/study/NCT02411448?tab=results"},{"endpoint":"Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])","unit":"%","arms":[{"name":"Part B: Ramucirumab+ Erlotinib","n":224,"value":76.3,"note":"95% CI 70.8 to 81.9; Figures from the ClinicalTrials.gov results section (first posted 2020-03-04), not from a publication"},{"name":"Part B: Placebo+ Erlotinib","n":225,"value":74.7,"note":"95% CI 69.0 to 80.3"}],"p":"0.7413","source":"https://clinicaltrials.gov/study/NCT02411448?tab=results"}]},"route":"/trials/nct02411448/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/"},{"id":"gefitinib","kind":"drug","name":"Gefitinib","route":"/drugs/gefitinib/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}],"paper":[{"id":"paper-nct02411448-lancet-oncol-2019","kind":"paper","name":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-nct02411448-lancet-oncol-2019/"},{"id":"paper-nct02411448-j-thorac-oncol-2025-update","kind":"paper","name":"RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC","route":"/key-papers/paper-nct02411448-j-thorac-oncol-2025-update/"}]}}